Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing the purchase of 1,000 shares of common stock at $5.00 per share in an underwritten public offering.
Key Highlights
- Reporting person: Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc.
- Transaction type: Purchase (transaction code P) of 1,000 shares of Common Stock, par value $0.0001 per share, acquired on November 9, 2026.
- Purchase price: $5.00 per share, described as the public offering price in an underwritten public offering of the issuer.
- Resulting ownership: Following the transaction, Taylor directly beneficially owns 590,989 shares of common stock.
- Filing basis: Form filed by one reporting person; no amendment to a prior filing was indicated.
CFO Andrew Lawrence Taylor Participates in Orchestra BioMed Public Offering
According to the Form 4 filed with the SEC on November 9, 2026, Andrew Lawrence Taylor, serving as Chief Financial Officer of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), acquired 1,000 shares of the company's Common Stock, par value $0.0001 per share. The transaction was coded "P," indicating an open-market or offering purchase, and was dated November 9, 2026.
The filing's footnote states that "these shares were purchased in an underwritten public offering of the Issuer at the public offering price of $5.00 per share." The total price paid for the acquired shares, based on the disclosed per-share price and share count, is consistent with a $5,000 transaction, though the filing itself states only the per-share price of $5.00 and the quantity of 1,000 shares. No transaction code indicating a Rule 10b5-1 plan was checked on the form.
Following the reported transaction, Taylor's direct beneficial ownership of Orchestra BioMed common stock stands at 590,989 shares, as reported in the filing. No derivative securities transactions were reported in Table II of the form. The form was signed by Andrew Taylor and dated November 9, 2026.
What Was Disclosed
Orchestra BioMed's CFO, Andrew Lawrence Taylor, disclosed a purchase of 1,000 shares of common stock at $5.00 per share through an underwritten public offering on November 9, 2026, bringing his direct beneficial ownership to 590,989 shares.





Please wait processing your request...